Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients.

Broyl A, Hose D, Lokhorst H, de Knegt Y, Peeters J, Jauch A, Bertsch U, Buijs A, Stevens-Kroef M, Beverloo HB, Vellenga E, Zweegman S, Kersten MJ, van der Holt B, el Jarari L, Mulligan G, Goldschmidt H, van Duin M, Sonneveld P.

Blood. 2010 Oct 7;116(14):2543-53. doi: 10.1182/blood-2009-12-261032. Epub 2010 Jun 23.

2.

Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells.

Zhan F, Hardin J, Kordsmeier B, Bumm K, Zheng M, Tian E, Sanderson R, Yang Y, Wilson C, Zangari M, Anaissie E, Morris C, Muwalla F, van Rhee F, Fassas A, Crowley J, Tricot G, Barlogie B, Shaughnessy J Jr.

Blood. 2002 Mar 1;99(5):1745-57.

3.
4.

The molecular classification of multiple myeloma.

Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, Epstein J, Yaccoby S, Sawyer J, Burington B, Anaissie E, Hollmig K, Pineda-Roman M, Tricot G, van Rhee F, Walker R, Zangari M, Crowley J, Barlogie B, Shaughnessy JD Jr.

Blood. 2006 Sep 15;108(6):2020-8. Epub 2006 May 25.

5.

Expression and prognostic significance of Oct2 and Bob1 in multiple myeloma: implications for targeted therapeutics.

Toman I, Loree J, Klimowicz AC, Bahlis N, Lai R, Belch A, Pilarski L, Reiman T.

Leuk Lymphoma. 2011 Apr;52(4):659-67. doi: 10.3109/10428194.2010.548535. Epub 2011 Jan 11.

PMID:
21438833
6.

Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling.

Chng WJ, Kumar S, Vanwier S, Ahmann G, Price-Troska T, Henderson K, Chung TH, Kim S, Mulligan G, Bryant B, Carpten J, Gertz M, Rajkumar SV, Lacy M, Dispenzieri A, Kyle R, Greipp P, Bergsagel PL, Fonseca R.

Cancer Res. 2007 Apr 1;67(7):2982-9.

7.

[Gene expression profiling of multiple myeloma].

Minvielle S.

Bull Cancer. 2003 Feb;90(2):127-30. Review. French.

PMID:
12660131
8.

Overexpression and involvement in migration by the metastasis-associated phosphatase PRL-3 in human myeloma cells.

Fagerli UM, Holt RU, Holien T, Vaatsveen TK, Zhan F, Egeberg KW, Barlogie B, Waage A, Aarset H, Dai HY, Shaughnessy JD Jr, Sundan A, Børset M.

Blood. 2008 Jan 15;111(2):806-15. Epub 2007 Oct 12.

9.

Multiple myeloma.

Harousseau JL, Shaughnessy J Jr, Richardson P.

Hematology Am Soc Hematol Educ Program. 2004:237-56. Review.

PMID:
15561686
10.

Gene expression profiling defines a high-risk entity of multiple myeloma.

Zhan FH, Barlogie B, John D S Jr.

Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2007 Apr;32(2):191-203. Review.

11.

Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma.

Mattioli M, Agnelli L, Fabris S, Baldini L, Morabito F, Bicciato S, Verdelli D, Intini D, Nobili L, Cro L, Pruneri G, Callea V, Stelitano C, Maiolo AT, Lombardi L, Neri A.

Oncogene. 2005 Apr 7;24(15):2461-73.

PMID:
15735737
12.

Translating a gene expression signature for multiple myeloma prognosis into a robust high-throughput assay for clinical use.

van Laar R, Flinchum R, Brown N, Ramsey J, Riccitelli S, Heuck C, Barlogie B, Shaughnessy JD Jr.

BMC Med Genomics. 2014 May 17;7:25. doi: 10.1186/1755-8794-7-25.

13.

Gene expression profiling of multiple myeloma reveals molecular portraits in relation to the pathogenesis of the disease.

Magrangeas F, Nasser V, Avet-Loiseau H, Loriod B, Decaux O, Granjeaud S, Bertucci F, Birnbaum D, Nguyen C, Harousseau JL, Bataille R, Houlgatte R, Minvielle S.

Blood. 2003 Jun 15;101(12):4998-5006. Epub 2003 Mar 6.

14.

Functional gene expression analysis of clonal plasma cells identifies a unique molecular profile for light chain amyloidosis.

Abraham RS, Ballman KV, Dispenzieri A, Grill DE, Manske MK, Price-Troska TL, Paz NG, Gertz MA, Fonseca R.

Blood. 2005 Jan 15;105(2):794-803. Epub 2004 Sep 23.

15.
16.

Comparison of gene expression profiling between malignant and normal plasma cells with oligonucleotide arrays.

De Vos J, Thykjaer T, Tarte K, Ensslen M, Raynaud P, Requirand G, Pellet F, Pantesco V, Rème T, Jourdan M, Rossi JF, Ørntoft T, Klein B.

Oncogene. 2002 Oct 3;21(44):6848-57.

17.

Insights from the gene expression profiling of multiple myeloma.

Claudio JO, Masih-Khan E, Stewart AK.

Curr Hematol Rep. 2004 Jan;3(1):67-73. Review.

PMID:
14695854
18.

High-risk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2/AGO2.

Zhou Y, Chen L, Barlogie B, Stephens O, Wu X, Williams DR, Cartron MA, van Rhee F, Nair B, Waheed S, Pineda-Roman M, Alsayed Y, Anaissie E, Shaughnessy JD Jr.

Proc Natl Acad Sci U S A. 2010 Apr 27;107(17):7904-9. doi: 10.1073/pnas.0908441107. Epub 2010 Apr 12.

19.

Molecular classification of multiple myeloma: a distinct transcriptional profile characterizes patients expressing CCND1 and negative for 14q32 translocations.

Agnelli L, Bicciato S, Mattioli M, Fabris S, Intini D, Verdelli D, Baldini L, Morabito F, Callea V, Lombardi L, Neri A.

J Clin Oncol. 2005 Oct 10;23(29):7296-306. Epub 2005 Aug 29.

20.

SAGE analysis highlights the importance of p53csv, ddx5, mapkapk2 and ranbp2 to multiple myeloma tumorigenesis.

Felix RS, Colleoni GW, Caballero OL, Yamamoto M, Almeida MS, Andrade VC, Chauffaille Mde L, Silva WA Jr, Begnami MD, Soares FA, Simpson AJ, Zago MA, Vettore AL.

Cancer Lett. 2009 Jun 8;278(1):41-8. doi: 10.1016/j.canlet.2008.12.022. Epub 2009 Jan 25.

PMID:
19171422
Items per page

Supplemental Content

Write to the Help Desk